These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 34219

  • 21. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA, Morris JG, Reid WG, Trafficante R.
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [Abstract] [Full Text] [Related]

  • 22. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV, Sternić NM, Filipović SR, Vojvodić NM, Kostić VS.
    Srp Arh Celok Lek; 1997 Feb; 125(7-8):203-6. PubMed ID: 9304232
    [Abstract] [Full Text] [Related]

  • 23. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [Abstract] [Full Text] [Related]

  • 24. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 25. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA.
    Mov Disord; 2005 Sep 01; 20(9):1205-9. PubMed ID: 15954135
    [Abstract] [Full Text] [Related]

  • 26. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep 01; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 27. [Abnormal involuntary movements in the elderly and their treatment (author's transl)].
    Delwaide PJ, Desseilles M.
    Sem Hop; 2002 Sep 01; 54(41-42):1247-9. PubMed ID: 32624
    [Abstract] [Full Text] [Related]

  • 28. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG, Scorticati MC, Micheli FE.
    Medicina (B Aires); 2000 Sep 01; 60(3):321-5. PubMed ID: 11050808
    [Abstract] [Full Text] [Related]

  • 29. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ.
    Neurobiol Dis; 2004 Mar 01; 15(2):171-6. PubMed ID: 15006686
    [Abstract] [Full Text] [Related]

  • 30. Apomorphine and diphasic dyskinesia.
    Durif F, Deffond D, Dordain G, Tournilhac M.
    Clin Neuropharmacol; 1994 Feb 01; 17(1):99-102. PubMed ID: 8149366
    [Abstract] [Full Text] [Related]

  • 31. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
    Bennett JP, Landow ER, Dietrich S, Schuh LA.
    Mov Disord; 1994 Jul 01; 9(4):409-14. PubMed ID: 7969207
    [Abstract] [Full Text] [Related]

  • 32. [Buccofacial dyskinesia of iatrogenic origin].
    Reynes P, Guichard M, Guiraud P.
    Rev Odontostomatol (Paris); 1983 Jul 01; 12(6):461-9. PubMed ID: 6142519
    [No Abstract] [Full Text] [Related]

  • 33. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 01; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 34. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV, Montejo González AL, Martín Carrasco M.
    Actas Esp Psiquiatr; 2003 Jun 01; 31(6):347-52. PubMed ID: 14639511
    [Abstract] [Full Text] [Related]

  • 35. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
    Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P.
    Mov Disord; 2002 Sep 01; 17(5):877-86. PubMed ID: 12360536
    [Abstract] [Full Text] [Related]

  • 36. [Dyskinetic syndromes in psychiatric patients (author's transl)].
    Lutrand JC, Ducamin JP.
    Sem Hop; 2002 Sep 01; 54(45-46):1465-8. PubMed ID: 34882
    [Abstract] [Full Text] [Related]

  • 37. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A.
    Parkinsonism Relat Disord; 2005 May 01; 11(3):151-5. PubMed ID: 15823479
    [Abstract] [Full Text] [Related]

  • 38. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul 01; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 39. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F, Rosa A, Comoy E.
    Rev Neurol (Paris); 1977 Jan 01; 133(1):3-11. PubMed ID: 847319
    [Abstract] [Full Text] [Related]

  • 40. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C, Jiménez A, Tolosa E, Bonastre M, Bové J.
    Synapse; 2004 Feb 01; 51(2):140-50. PubMed ID: 14618681
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.